SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dry eye disease
Drug Development
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
The company announced Tuesday that despite the error preventing the analysis of late-stage results, the FDA confirmed that data from other completed trials are sufficient to support an NDA submission in the first quarter of 2025.
August 27, 2024
 · 
1 min read
 · 
Annalee Armstrong
D2C Direct to Consumer, eCommerce strategy aimed directly at consumer, Virtual Screen Technology
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
 · 
5 min read
 · 
Mollie Barnes
View of Boston architecture, featuring contemporary and historic buildings
Job Trends
Massachusetts’ Biopharma Jobs Grew at Slowed Rate in 2023: Report
Massachusetts’ biopharma jobs increased 2.6% in 2023, according to the MassBio Industry Snapshot. Whether the state’s jobs grow in 2024 remains to be seen based on this year’s layoffs and seemingly slowed hiring based on BioSpace data.
August 27, 2024
 · 
5 min read
 · 
Angela Gabriel
External view of Eli Lilly's world headquarters in Indianapolis
Obesity
Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials
Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other incretin obesity treatments.
August 27, 2024
 · 
3 min read
 · 
Tristan Manalac
3D illustration of tow GLP-1 therapy autoinjectors
Drug pricing
Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study
The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.
August 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Signage outside Express Scripts' headquarters in Missouri
Pharmacy benefit managers
Cigna to Remove AbbVie’s Humira From Formularies, Putting More Pressure on Blockbuster
Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.
August 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono
With the FDA’s rejection of Ordspono in March, Monday’s green light from the European Commission marks the first approval worldwide and the first regulatory victory for Regeneron’s bispecific antibody platform.
August 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Human hands symbolizing teamwork working on a pie chart. Arms point fingers hold pieces diagram chart.
Mergers & acquisitions
UCB Offloads Neurology, Allergy Portfolio in China for $680M
Belgium-based biopharma UCB is selling its Chinese neurology and allergy business to Singapore asset management firm CBC Group and Abu Dhabi investment company Mubadala.
August 26, 2024
 · 
1 min read
 · 
Annalee Armstrong
Bayer office in Basel, Switzerland
Layoffs
Bayer to Lay Off 150 in Basel, Switzerland
The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly half of the executive leadership team.
August 26, 2024
 · 
1 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS